Vaccine Study Links

Antivaxxer just means parents with legitimate questions.
It is good to question the narrative and motives of government and big pharma, or do we blindly hand our kids over for corporate profits just because the man on TV is paid to tell us to?
Why did Congress make it impossible to sue vaccine manufacturers? Why have the number of vaccines required increased by 400%?
Why are newborns required to get vaccines when they don’t have an immune system?
Why would all newborns need a Hep B vaccine that is an STD?
Why is it better that more people die from the measles vaccine than die from measles?
Do adjuvants like nano particles of aluminum (a neurotoxin) cross the blood/brain barrier?
Why have child illnesses like cancers, auto-immune, severe allergies, SIDS and neurological diseases like ADHD and autistic spectrum disorders increased?
“Science” is the practice of testing hypothesis through reproducible experiments to come to a theory.
“Science” is not a religion that you can blindly trust, because it has been funded, politicized, and advertised by monied, globalist interests.
The National Vaccine Injury Compensation Program (VICP) is the perfect example of regulatory capture, when lobbyists convinced “lawmakers” to hide vaccine efficacy and side effects by throwing them to a secret court.

Percentage of US children who have chronic health conditions on the rise

Diseases such as asthma and attention deficit hyperactivity disorder have increased at a disproportionate rate among children living in poverty, according to new research being presented at the Pediatric Academic Societies 2016 Meeting

Non-linear dose-response of aluminium hydroxide adjuvant particles: Selective low dose neurotoxicity

Aluminium (Al) oxyhydroxide (Alhydrogel®), the main adjuvant licensed for human and animal vaccines, consists of primary nanoparticles that spontaneously agglomerate. Concerns about its safety emerged following recognition of its unexpectedly long-lasting biopersistence within immune cells in some individuals, and reports of chronic fatigue syndrome, cognitive dysfunction, myalgia, dysautonomia and autoimmune/inflammatory features temporally linked to multiple Al-containing vaccine administrations. Mouse experiments have documented its capture and slow transportation by monocyte-lineage cells from the injected muscle to lymphoid organs and eventually the brain. The present study aimed at evaluating mouse brain function and Al concentration 180 days after injection of various doses of Alhydrogel® (200, 400 and 800 μg Al/kg of body weight) in the tibialis anterior muscle in adult female CD1 mice. Cognitive and motor performances were assessed by 8 validated tests, microglial activation by Iba-1 immunohistochemistry, and Al level by graphite furnace atomic absorption spectroscopy.

An unusual neuro-toxicological pattern limited to a low dose of Alhydrogel® was observed. Neurobehavioural changes, including decreased activity levels and altered anxiety-like behaviour, were observed compared to controls in animals exposed to 200 μg Al/kg but not at 400 and 800 μg Al/kg. Consistently, microglial number appeared increased in the ventral forebrain of the 200 μg Al/kg group. Cerebral Al levels were selectively increased in animals exposed to the lowest dose, while muscle granulomas had almost completely disappeared at 6 months in these animals.

We conclude that Alhydrogel® injected at low dose in mouse muscle may selectively induce long-term Al cerebral accumulation and neurotoxic effects. To explain this unexpected result, an avenue that could be explored in the future relates to the adjuvant size since the injected suspensions corresponding to the lowest dose, but not to the highest doses, exclusively contained small agglomerates in the bacteria-size range known to favour capture and, presumably, transportation by monocyte-lineage cells. In any event, the view that Alhydrogel® neurotoxicity obeys “the dose makes the poison” rule of classical chemical toxicity appears overly simplistic.

Read More:

A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States


Autism spectrum disorder (ASD) is defined by standardized criteria of qualitative impairments in social interaction, qualitative impairments in communication, and restricted and stereotyped patterns of behavior, interests, and activities. A significant number of children diagnosed with ASD suffer a loss of previously-acquired skills, which is suggestive of neurodegeneration or a type of progressive encephalopathy with an etiological pathogenic basis occurring after birth. To date, the etiology of ASD remains under debate, however, many studies suggest toxicity, especially from mercury (Hg), in individuals diagnosed with an ASD. The present study evaluated concerns about the toxic effects of organic-Hg exposure from Thimerosal (49.55% Hg by weight) in childhood vaccines by conducting a two-phased (hypothesis generating/hypothesis testing) study with documented exposure to varying levels of Thimerosal from vaccinations.

Read More:

Allergic reactions after vaccination: translating guidelines into clinical practice.

Vaccination represents one of the most powerful medical interventions on global health. Despite being safe, sustainable, and effective against infectious and in some cases also non-infectious diseases, it’s nowadays facing general opinion’s hesitancy because of a false perceived risk of adverse events. Adverse reactions to vaccines are relatively rare, instead, and those recognizing a hypersensitivity mechanism are even rarer. The purpose of this review is to offer a practical approach to adverse events after vaccination, focusing on immune-mediated reactions with particular regard to their recognition, diagnosis and management. According to clinical features, we propose an algorythm for allergologic work-up, which helps in confirming hypersensitivity to vaccine, nonetheless ensuring access to vaccination. Finally, a screening questionnaire is included, providing criteria for immunisation in specialized care settings.

Read More:

The role of mercury in the pathogenesis of autism

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder of unknown etiology in most cases. Studies of monozygotic twins report an average 60% concordance rate, indicating a role for both genetic and environmental factors in disease expression.1 Recent reviews in environmental health have suggested that early exposure to hazardous substances may underlie some cases of neurodevelopmental disorders, including ADHD, learning disabilities, and speech/language difficulties.2In 1999, thimerosal used as a vaccine preservative was identified as a widespread source of organic mercury exposure in infants.3 Mercury (Hg), a heavy metal, is considered highly neurotoxic.4 The amount of mercury in vaccines, while small, exceeded USEPA safety guidelines on a cumulative basis.3 Certain individuals may exhibit severe adverse reactions to low doses of Hg which are otherwise largely benign to the majority of those exposed.5 Some individuals with idiopathic autism spectrum disorder may represent such a sensitive population. As summarized in this paper, disease characteristics suggest this possibility: (a) ASD traits are known to arise from mercury exposure; (b) onset of ASD symptoms is temporally associated with administration of immunizations; (c) the reported increase in the prevalence of autism in the 1990s closely follows the introduction of two mercury-containing vaccines; and (d) elevated mercury has been detected in biological samples of autistic patients. Since ASD may now affect as many as one in 150 US children,6 and since thimerosal is still used in many products worldwide, confirmation of thimerosal as an environmental agent in autism pathogenesis has important societal and patient implications.

Read More:

A Dose-Response Relationship between Organic Mercury Exposure from Thimerosal-Containing Vaccines and Neurodevelopmental Disorders

A hypothesis testing case-control study evaluated concerns about the toxic effects of organic-mercury (Hg) exposure from thimerosal-containing (49.55% Hg by weight) vaccines on the risk of neurodevelopmental disorders (NDs). Automated medical records were examined to identify cases and controls enrolled from their date-of-birth (1991–2000) in the Vaccine Safety Datalink (VSD) project. ND cases were diagnosed with pervasive developmental disorder (PDD), specific developmental delay, tic disorder or hyperkinetic syndrome of childhood. In addition, putative non-thimerosal-related outcomes of febrile seizure, failure to thrive and cerebral degenerations were examined. The cumulative total dose of Hg exposure from thimerosal-containing hepatitis B vaccine (T-HBV) administered within the first six months of life was calculated. On a per microgram of organic-Hg basis, PDD (odds ratio (OR) = 1.054), specific developmental delay (OR = 1.035), tic disorder (OR = 1.034) and hyperkinetic syndrome of childhood (OR = 1.05) cases were significantly more likely than controls to receive increased organic-Hg exposure. By contrast, none of the non-thimerosal related outcomes were significantly more likely than the controls to have received increased organic-Hg exposure. Routine childhood vaccination may be an important public health tool to reduce infectious disease-associated morbidity/mortality, but the present study significantly associates organic-Hg exposure from T-HBV with an increased risk of an ND diagnosis.

Read More:

Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity

We have examined the neurotoxicity of aluminum in humans and animals under various conditions, following different routes of administration, and provide an overview of the various associated disease states. The literature demonstrates clearly negative impacts of aluminum on the nervous system across the age span. In adults, aluminum exposure can lead to apparently age-related neurological deficits resembling Alzheimer’s and has been linked to this disease and to the Guamanian variant, ALS–PDC. Similar outcomes have been found in animal models. In addition, injection of aluminum adjuvants in an attempt to model Gulf War syndrome and associated neurological deficits leads to an ALS phenotype in young male mice. In young children, a highly significant correlation exists between the number of pediatric aluminum-adjuvanted vaccines administered and the rate of autism spectrum disorders. Many of the features of aluminum-induced neurotoxicity may arise, in part, from autoimmune reactions, as part of the ASIA syndrome.

Read More:

Neurological adverse events associated with vaccination.

Public tolerance to adverse reactions is minimal. Several reporting systems have been established to monitor adverse events following immunization. The present review summarizes data on neurologic complications following vaccination, and provides evidence that indicates whether they were directly associated with the vaccines. These complications include autism (measles vaccine), multiple sclerosis (hepatitis B vaccine), meningoencephalitis (Japanese encephalitis vaccine), Guillain-Barré syndrome and giant cell arteritis (influenza vaccine), and reactions after exposure to animal rabies vaccine. Seizures and hypotonic/hyporesponsive episodes following pertussis vaccination and potential risks associated with varicella vaccination, as well as vaccine-associated paralytic poliomyelitis following oral poliovirus vaccination, are also described. In addition, claims that complications are caused by adjuvants, preservatives and contaminants [i.e. macrophagic myofasciitis (aluminium), neurotoxicity (thimerosal), and new variant Creutzfeldt-Jakob disease (bovine-derived materials)] are discussed.

Read More:

Inflammatory Responses to Trivalent Influenza Virus Vaccine Among Pregnant Women


In the U.S., seasonal trivalent influenza vaccination (TIV) is currently universally recommended for all pregnant women. However, data on the maternal inflammatory response to vaccination is lacking and would better delineate the safety and clinical utility of immunization. In addition, for research purposes, vaccination has been used as a mild immune trigger to examine in vivo inflammatory responses in nonpregnant adults. The utility of such a model in pregnancy is unknown. Given the clinical and empirical justifications, the current study examined the magnitude, time course, and variance in inflammatory responses following seasonal influenza virus vaccination among pregnant women.

Read More:!po=5.55556

Hypothesis: conjugate vaccines may predispose children to autism spectrum disorders.

The first conjugate vaccine was approved for use in the US in 1988 to protect infants and young children against the capsular bacteria Haemophilus influenzae type b (Hib). Since its introduction in the US, this vaccine has been approved in most developed countries, including Denmark and Israel where the vaccine was added to their national vaccine programs in 1993 and 1994, respectively. There have been marked increases in the reported prevalence of autism spectrum disorders (ASDs) among children in the US beginning with birth cohorts in the late 1980s and in Denmark and Israel starting approximately 4-5 years later. Although these increases may partly reflect ascertainment biases, an exogenous trigger could explain a significant portion of the reported increases in ASDs. It is hypothesized here that the introduction of the Hib conjugate vaccine in the US in 1988 and its subsequent introduction in Denmark and Israel could explain a substantial portion of the initial increases in ASDs in those countries. The continuation of the trend toward increased rates of ASDs could be further explained by increased usage of the vaccine, a change in 1990 in the recommended age of vaccination in the US from 15 to 2 months, increased immunogenicity of the vaccine through changes in its carrier protein, and the subsequent introduction of the conjugate vaccine for Streptococcus pneumoniae. Although conjugate vaccines have been highly effective in protecting infants and young children from the significant morbidity and mortality caused by Hib and S. pneumoniae, the potential effects of conjugate vaccines on neural development merit close examination. Conjugate vaccines fundamentally change the manner in which the immune systems of infants and young children function by deviating their immune responses to the targeted carbohydrate antigens from a state of hypo-responsiveness to a robust B2 B cell mediated response. This period of hypo-responsiveness to carbohydrate antigens coincides with the intense myelination process in infants and young children, and conjugate vaccines may have disrupted evolutionary forces that favored early brain development over the need to protect infants and young children from capsular bacteria.

Read More:

Elevated levels of measles antibodies in children with autism.

Virus-induced autoimmunity may play a causal role in autism. To examine the etiologic link of viruses in this brain disorder, we conducted a serologic study of measles virus, mumps virus, and rubella virus. Viral antibodies were measured by enzyme-linked immunosorbent assay in the serum of autistic children, normal children, and siblings of autistic children. The level of measles antibody, but not mumps or rubella antibodies, was significantly higher in autistic children as compared with normal children (P = 0.003) or siblings of autistic children (P <or= 0.0001). Furthermore, immunoblotting of measles vaccine virus revealed that the antibody was directed against a protein of approximately 74 kd molecular weight. The antibody to this antigen was found in 83% of autistic children but not in normal children or siblings of autistic children. Thus autistic children have a hyperimmune response to measles virus, which in the absence of a wild type of measles infection might be a sign of an abnormal immune reaction to the vaccine strain or virus reactivation.

Read More:

Simian Virus 40 and Human Disease

The inadvertent and unrecognized presence of simian virus 40 (SV40) in the commercial inactivated Salk poliovaccines administered between 1955 and 1963 resulted in the potential exposure of millions of individuals, in the United States and elsewhere, to this polyomavirus of the rhesus macaque [1]. Many of the monkeykidney cultures used to prepare poliovirus pools were infected with the indigenous SV40. Soon after its discovery in 1960 [2], SV40 was found to be oncogenic in laboratory animals [3]. Therefore, the possibility that SV40 may cause human disease, particularly cancers, has been a topic of interest since the 1960s [4]. This debate has intensified during the past decade because several groups of investigators, using polymerase chain reaction (PCR) amplification methodology, have detected SV40 genomic sequences in a number of human cancers. These investigators have suggested that the virus contributes to the development of mesothelioma, osteosarcoma, pediatric and adult brain tumors, and non-Hodgkin lymphomas [5–8]. The reported presence of SV40 in tumors in individuals born after 1963 would seem to imply that SV40 is now established as a human infection circulating in communities via person-to-person contact [8]. Other investigators have been skeptical of these claims [9–12]; several groups have not been able to detect SV40 sequences in the aforementioned tumors [13–20], and epidemiologic studies have not revealed an increased risk of these cancers in populations exposed to SV40-contaminated poliovaccines or adenovirus vaccines [21–23]. In addition to a large number of scientific publications, the controversy has spawned a report by the Institute of Medicine [24], a book in the popular press [25], and litigations. The evidence for the pathogenicity of SV40 in humans can be conveniently examined in 3 parts: (1) the nature of the human response after exposure to SV40, (2) the evidence that infection with SV40 has become established in humans, and (3) the evidence that infection with SV40 contributes to the development of human cancers.

Read More:

Section 1.0 Adverse reaction (AR) case reporting through Canada Vigilance

AR cases for the following health products marketed in Canada are reported through Canada Vigilance: prescription and non-prescription medications; natural health products; biologics (includes biotechnology products, vaccines, fractionated blood products, human blood and blood components products, as well as human cells, tissues and organs); radiopharmaceuticals; and disinfectants and sanitizers with disinfectant claims.

AR cases frequently contain multiple reported reactions which are coded in the Canada Vigilance database using the Medical Dictionary for Regulatory Activities (MedDRA). MedDRA uses a hierarchy in order to group similar conditions or reactions together.

Annual trends for the adverse reaction case reports of health products and medical device problem incidents to Health Canada (2008-2017)

1.1 Trends in AR reporting (2008-2017)

Since 2008, there has been a continuous increase in AR case reporting to Health Canada from 15,551 cases in 2008 to 64,617 cases in 2017 (Figure 1).

Read More:

Adverse events following immunization with vaccines containing adjuvants.

A traditional infectious disease vaccine is a preparation of live attenuated, inactivated or killed pathogen that stimulates immunity. Vaccine immunologic adjuvants are compounds incorporated into vaccines to enhance immunogenicity. Adjuvants have recently been implicated in the new syndrome named ASIA autoimmune/inflammatory syndrome induced by adjuvants. The objective describes the frequencies of post-vaccination clinical syndrome induced by adjuvants. We performed a cross-sectional study; adverse event following immunization was defined as any untoward medical occurrence that follows immunization 54 days prior to the event. Data on vaccinations and other risk factors were obtained from daily epidemiologic surveillance. Descriptive statistics were done using means and standard deviation, and odds ratio adjusted for potential confounding variables was calculated with SPSS 17 software. Forty-three out of 120 patients with moderate or severe manifestations following immunization were hospitalized from 2008 to 2011. All patients fulfilled at least 2 major and 1 minor criteria suggested by Shoenfeld and Agmon-Levin for ASIA diagnosis. The most frequent clinical findings were pyrexia 68%, arthralgias 47%, cutaneous disorders 33%, muscle weakness 16% and myalgias 14%. Three patients had diagnosis of Guillain-Barre syndrome, one patient had Adult-Still’s disease 3 days after vaccination. A total of 76% of the events occurred in the first 3 days post-vaccination. Two patients with previous autoimmune disease showed severe adverse reactions with the reactivation of their illness. Minor local reactions were present in 49% of patients. Vaccines containing adjuvants may be associated with an increased risk of autoimmune/inflammatory adverse events following immunization.

Read More:

Public Health Officials Know: Recently Vaccinated Individuals Spread Disease

 A statement on the website of St. Jude’s Hospital warns parents not to allow people to visit children undergoing cancer treatment if they have received oral polio or smallpox vaccines within four weeks, have received the nasal flu vaccine within one week, or have rashes after receiving the chickenpox vaccine or MMR (measles, mumps, rubella) vaccine.2

“The public health community is blaming unvaccinated children for the outbreak of measles at Disneyland, but the illnesses could just as easily have occurred due to contact with a recently vaccinated individual,” says Sally Fallon Morell, president of the Weston A. Price Foundation. The Foundation promotes a healthy diet, non-toxic lifestyle and freedom of medical choice for parents and their children. “Evidence indicates that recently vaccinated individuals should be quarantined in order to protect the public.”

Scientific evidence demonstrates that individuals vaccinated with live virus vaccines such as MMR (measles, mumps and rubella), rotavirus, chicken pox, shingles and influenza can shed the virus for many weeks or months afterwards and infect the vaccinated and unvaccinated alike. 3,4,5,6,7,8,9,10.11.12

Read More:

WHO exposed in Prenatal Mass Murder Operation in Kenya

The World Health Organization (WHO) has been discovered in a criminal, secret mass sterilization effort in Kenya under the guise of administering shots to (only) women against tetanus. The Kenya Catholic Doctors Association has discovered an antigen in the tetanus vaccines that causes miscarriages in a vaccine that is being administered to 2.3 million girls and women by the World Health Organization and UNICEF. [1] It Isn’t the first time WHO has tried secret prenatal mass murder in developing countries.

Dr. Muhame Ngare, spokesman for the Catholic Doctors Association, from Mercy Medical Centre in Nairobi clarified, “We sent six samples from around Kenya to laboratories in South Africa. They tested positive for the HCG antigen. They were all laced with HCG. This proved right our worst fears; that this WHO campaign is not about eradicating neonatal tetanus but a well-coordinated forceful population control mass sterilization exercise using a proven fertility regulating vaccine. This evidence was presented to the Ministry of Health before the third round of immunization, but was ignored.” [2]

According to Ngare, the doctors became alarmed when they were informed by WHO and the Nigerian Health Ministry that this tetanus vaccine involved an unprecedented five shots over more than two years and was applied only to women of child-bearing years. He noted, “Usually we give a series three shots over two to three years, we give it anyone who comes into the clinic with an open wound, men, women or children. If this is intended to inoculate children in the womb, why give it to girls starting at 15 years? You cannot get married till you are 18. The usual way to vaccinate children is to wait till they are six weeks old.” [3]

Read More:

The Swedish Parliament voted against all vaccine motions (2017)

Today, the Riksdag decision regarding Social Committee’s Report 2016/17: SoU7, which included a variety of measures for public health. What did a large part of the population to monitor this particular case was that it contained several bills that would pave the way for both more vaccinations forced vaccination. This was something that involved many, not just those who have opted out of the vaccine, but also people who are for the vaccine, but certainly do not want to see any coercion.

NHF Sweden sent a letter to the National Committee and explained that it would violate our constitutional law on the introduction of forced vaccination, or mandatory vaccination as alleged in Arkel Stens exercise. Many others have also sent letters and many have called Social Committee and parliamentarians. Parliamentary Politicians have certainly noticed that there is massive opposition to all forms of coercion with regard to vaccination.

Read More:


Below is a list of videos (and some articles) where medical doctors and PhD scientists come forward to discuss the unhealthy effects of vaccines. Each professional presents documented research, facts and statistics to prove,  when taken in its’ totality, that 1) vaccines aren’t safe 2) vaccines aren’t effective 3) vaccines haven’t been proven to increase immunity or resistance to disease and 4) that vaccines only decrease the health of the people they’re injected into. Vaccines are also proven and documented in many cases to kill instantly and cripple for life. The situations of instant child death and permanent injury, due to vaccination, are well documented in the linked information.

Read More:

An aluminium adjuvant in a vaccine is an acute exposure to aluminium

Conclusion: is the amount of aluminium in a vaccine ‘minuscule’?

Simply by looking at just one dose of a vaccine given at 8 weeks of age it is abundantly clear that science does not support this contention, as espoused regularly by many infant paediatricians. In fact, just a single dose of Infanrix Hexa vaccine represents a severe acute exposure to systemically available aluminium. A single dose of this vaccine is equivalent to the exposure to aluminium that an infant would receive from 150 days breast-feeding. It is equivalent to 25 times the daily dose of aluminium received from the most contaminated of infant formulas. It is pertinent to emphasise that an infant would receive a further two doses of this vaccine during the aforementioned 150 day period. It is also highly relevant that other aluminium adjuvanted vaccines, for example Prevenar 13 ( and Men B ( are also part of the infant vaccine schedule for this same period. In the United Kingdom it is not uncommon for an infant to receive all three of these aluminium adjuvanted vaccines on the same day. A combined daily exposure of 1.445 mg of aluminium (according to the manufacturer’s data), equivalent to 260 days exposure to aluminium through breast feeding. Exposure to aluminium through a vaccine is, in comparison to diet, an acute exposure and an infant’s physiology will respond differently to exposure to a high concentration of aluminium over a very short time period. The latter, acute versus chronic exposure, while not yet being taken into account in infant vaccination programmes, must now be considered to help to ensure that future vaccination schedules are safe. Currently the EMA and the FDA limit the aluminium content of a vaccine to 1.25 mg (See for example, This limit is based upon the aluminium adjuvant’s efficacy in inducing antibody titres. Perhaps now is the time to revise this limit based upon additional factors of vaccine safety.

Read More: